非転移性去勢抵抗性前立腺がんでPSAが急上昇している患者に対する抗アンドロゲン薬エンザルタミド、第Ⅲ相試験PROSPERでプラセボ群に対し転移または死亡のリスクを71%減少【NEJM】

N Engl J Med 2018; 378: 2465-2474

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

BACKGROUND
Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would delay metastasis in men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*